PTSD rate at 3 months · adults experiencing acute traumatic stress symptoms
It is very uncertain whether hydrocortisone changes PTSD rate at 3 months compared with placebo (very low certainty).
1 finding from 1 review
Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts due to adverse events · adults (aged 18‐85)
It is very uncertain whether comparison 5: SNRIs changes treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (very low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
Comparison 6: SSRIs probably leads to lower treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 6: SSRIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
Comparison 7: TCAs may leads to lower treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (low certainty).
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 7: TCAs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 1: Alpha‐blockers showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
It is very uncertain whether comparison 2: Antipsychotics changes treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (very low certainty).
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 2: Antipsychotics showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 3: MAOIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
Comparison 4: NaSSAs may leads to lower treatment efficacy ‐ Treatment response, as measured by the Global… compared with placebo (low certainty).
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 4: NaSSAs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gambling symptom severity · treatment of disordered and problem gambling
1 finding from 1 review
Gambling expenditure ‐ not measured · treatment of disordered and problem gambling
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gambling frequency ‐ not measured · treatment of disordered and problem gambling
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time spent gambling ‐ not measured · treatment of disordered and problem gambling
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found